Incyte boosted by the bulls at Barclays

|About: Incyte Corporation (INCY)|By:, SA News Editor

Citing data Incyte (INCY +3.4%) presented at the American Association for  Cancer Research meeting this week, Barclays reiterates an Overweight rating and boosts the price target to $135.

The indoleamine 2, 3-dioxygenase (IDO) market is tilting in favor of Incyte’s epacadostat, says the team.

Conversations with rheumatologists have them more confident the FDA will approve Olumiant (baricitinib), as doctors prefer it to Pfizer’s Xeljanz, given its safety profile.

Source: Barron's

Previously: Price target boost for Eli Lilly (April 7)